glp 1 agonist alzheimer Could diabetes and weight loss drugs treat Alzheimer's disease? GLP-1 Agonists and Dementia -

Glucagon-like peptide-1: a promising agent for cardioprotection during myocardial ischemia

doi: 10.1016/j.jacc.2024.11.001

"When hunger is reduced, people finally feel able to follow the healthy steps they were told to take for years. Globally, more than 1 billion people currently live with obesity, a number projected to reach 2 billion by 2030

Manufacturers did not design these drugs for people with moderate weight who want to lose additional weight

We do not prescribe compounded GLP-1 medications

Serious and Rare Adverse Effects of Incretin Mimetics While the vast majority of glp-1 peptides side effects are mild and gastrointestinal in nature, researchers must remain vigilant regarding rare but severe adverse events that have been flagged in pharmacovigilance databases and animal studies